Mental Health

Healthline Media and BEAM Announce Black Trans Women’s Wellness and Mental Health Grants

Healthline Media in partnership with the Black Emotional and Mental Health Collective (BEAM) has announced the Black Trans Women’s Wellness and Mental Health Grants. The new program will award three grants of up to $10K each to Black trans women-led projects that support Black trans women’s mental health. Applications are now open, and winners will be announced in January 2022. The grants are part…

HEAL Launches Its Digital Support Platform for Survivors of Sexual Abuse

HEAL Innovations, a company empowering survivors of sexual abuse to overcome their past and reclaim their lives, today announced the launch of its digital healing service website. Founder Wendy M. Johnson HEAL’s Founder Wendy M. Johnson is the author the HEAL Curriculum, an educational 14-session curriculum for survivors to go through. The company was incubated in the Harvard Innovation Labs – Venture…

Virtual Eating Disorder Clinic Equip Expands Geographically and Now Reaches Half the U.S. Population

Equip, a leading provider of virtual, evidence-based eating disorder treatment in the U.S., today announced the expansion of its services into four major markets – Colorado, Florida, Georgia, and Illinois. With this growth, Equip is now able to serve half the country – over 160 million patients and their families – through Family-Based Treatment (FBT) delivered at home for lasting recovery. “We’ve long known how widespread…

Field Trip Pursues Postpartum Depression and Treatment Resistant Depression as Lead Indications for FT-104, Its Novel Psychedelic Compound

Field Trip, a leader in the development and delivery of psychedelic therapies, has announced the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecules. Its first molecule in development, FT-104, a prodrug, is a synthetic serotonin-2A…

Why Wearables Company Bellabeat Is Investing $10M in Solutions and Research Targeting Postnatal Depression

Bellabeat, known for its wearable fitness trackers has recently announced that the company plans to invest $10M in research and solutions addressing postnatal depression this year. This investment is a call to action and aims to bring more attention to postnatal depression as well as incentivize institutes, companies, and clinics in the space to look for viable, holistic health solutions regarding the…

Healthline Media Deepens Its Commitment to Black Mental Health with an Investment in BEAM’s Black Wellness Innovation Fund

Healthline Media has expanded its ongoing partnership with the Black Emotional and Mental Health Collective (BEAM) by becoming the premier partner in BEAM’s Black Wellness Innovation Fund with a $100K contribution. In honor of BIPOC Mental Health Awareness Month, which BEAM has reframed as “Mental Health Liberation Month”, BEAM is seeking to expand the Black Wellness Innovation Fund to support underserved Black…

MedAnswers and Organic Conceptions Team Up to Deliver Emotional Health Insights to the FertilityAnswers App Community

Health impact startup, MedAnswers has announced it has partnered with Organic Conceptions, an emotional health and wellness company for those challenged by fertility issues. Through the FertilityAnswers mobile application, MedAnswers now provides the clinically validated survey, FertiQol, to its patient health profile to assess its users’ emotional wellness and quality of life as it relates to their ability to cope with struggling…

Investigational Pill for Postpartum Depression Shows Promise in Clinical Trial Led by the Feinstein Institutes

Scientists from The Feinstein Institutes for Medical Research have announced the publication of results from a phase 3 clinical trial looking at the safety and efficacy of the oral neuroactive steroid zuranolone (30mg) in the treatment of patients with postpartum depression (PPD). The findings published in the Journal of the American Medical Association (JAMA) Psychiatry showed that after two weeks of daily treatment, women treated…